Figuring out which anaplastic lymphoma kinase inhibitor to use first in ALK-positive NSCLC, and handicapping the prospects for those coming through pipelines, has turned into a major challenge for oncologists, especially as resistance grows to New York-based Pfizer Inc.'s Xalkori (crizotinib), approved in August 2011 as a first-line treatment.